In April 2024, the National Medical Products Administration (NMPA) of China approved the use of PLB-1001 (Britinib) in patients with astrocytoma, IDH mutant who carried the PTPRZ1-MET fusion gene. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).